Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Fourpath Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 20.0% in ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Optas LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 15.6% during the 4th quarter, according to ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

We recently published a list of Jim Cramer is Talking About These 10 Stocks. In this article, we are going to take a look at ...